Navigation Links
Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
Date:11/3/2011

osely with key opinion leaders and experts in obstetrics, retinal care and genetics.  Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests.  Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory testing services.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding expectations of continued progress on initiatives to enhance revenue growth and manage costs in the last quarter of 2011.  Sequenom's plans to focus on its priority programs for the near future, expected performance and benefits of the MaterniT21 LDT, plans to grow the MaterniT21 LDT and other offerings, expansion of organizational capabilities and processing capacities, Sequenom's collaboration plans with LifeCodexx AG and expected performance under its licensing agreement with LifeCodexx AG and LifeCodexx AG's intentions regarding the introduction and timing of introduction of a test in selected European markets, Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions and dedication to development and commercialization of laboratory-developed genetic testing services for prenatal and eye conditions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the collaborative efforts of other parties, Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as the MaterniT21 LDT, prenatal and other diagnostics and laborator
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... to participate in the 19th Annual Piper Jaffray,Health Care ... on Tuesday,November 27, 2007. Steven G. Anderson, president ... beginning at approximately 1:30 p.m. EST. CryoLife,s live ...
... pm ET on November 27, 2007, CAMBRIDGE, Mass., ... today announced its participation,in the Lazard Capital Markets Fourth ... at the New York Palace Hotel in New York,City. ... be presenting at 2:00 pm ET on Tuesday, November ...
... Scientists have announced,that they successfully reprogrammed adult ... of patient-specific medical treatments and,research without the need ... the Discovery Institute,s Senior Fellow in Bioethics,and author ... hailed the,breakthrough as demonstrating that ethical science is ...
Cached Biology Technology:CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York 2Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... from the north-central U.S. and beyond will convene in Kalamazoo, ... and discuss new science, expand on existing science, and explore ... a special emphasis on the Great Lakes. Events include a ... by William F. Ruddiman titled, "When Did We Transform Earth,s ...
... York, NY (April 18, 2013) An excess of ... psychosis in people who are at risk for schizophrenia, ... Center (CUMC) published in the current issue of ... diagnostic tool for identifying those at risk for schizophrenia ...
... IOF Medal of Achievement has been presented today to ... Department of Internal Medicine, Hospital del Mar, Director of ... Institute of Medical Research and Professor of Medicine at ... Foundation (IOF) awards the IOF Medal of Achievement every ...
Cached Biology News:Kalamazoo center of geologic focus this May 2High levels of glutamate in brain may kick-start schizophrenia 2IOF Medal of Achievement awarded to Professor Adolfo Diez-Perez 2
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: